Home › Funds › Cardinal Strategic Wealth Guidance › ABT

Cardinal Strategic Wealth Guidance position in ABT

ABBOTT LABORATORIES · Health Care

Cardinal Strategic Wealth Guidance reported holding 2,774 shares of ABT (ABBOTT LABORATORIES) in its Q3 2026 13F filing — a position valued at US$274K, representing 0.06% of its reported portfolio and ranking #48 among its reported holdings. Cardinal Strategic Wealth Guidance has disclosed ABT holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

Latest position (Q3 2026)2.77K sh
Reported value held$274.15K
Portfolio Weight0.06%
First reportedQ3 2023
Last changeHold
Updated2026-11-13

Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR

How Cardinal Strategic Wealth Guidance's ABT position evolved

Cardinal Strategic Wealth Guidance first disclosed a stake in ABT in Q3 2023 at 2,712 shares (US$263K). The position peaked in Q2 2025 at 2,784 shares, worth US$379K. Across 13 filings, Cardinal Strategic Wealth Guidance increased the stake 2 time(s), trimmed it 1 time(s) and left it unchanged 9 time(s). The most recent filing (Q3 2026) shows 2,774 shares valued at US$274K.

Quarter by quarter

QuarterSharesValueChange
Q3 2023 2.71K $262.66K New
Q4 2023 2.71K $298.51K Hold
Q1 2024 2.71K $308.25K Hold
Q2 2024 2.79K $289.91K Add
Q3 2024 2.79K $318.09K Hold
Q4 2024 2.79K $315.58K Hold
Q1 2025 2.79K $370.09K Hold
Q2 2025 2.78K $378.65K Hold
Q3 2025 2.78K $372.89K Hold
Q4 2025 2.78K $348.81K Hold
Q1 2026 2.84K $291.79K Add
Q2 2026 2.77K $251.71K Reduce
Q3 2026 2.77K $274.15K Hold

Dots on the line are colored by change type; missing quarters mean no position was reported.

About ABT and 13F data

ABT (ABBOTT LABORATORIES) is a Health Care company. 21 other funds we track also report a position in ABT — the largest reported positions include Vanguard Group (US$22.00B), Charles Schwab Investment Management (US$5.41B), CHARLES SCHWAB INVESTMENT MANAGEMENT INC (US$5.41B). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding ABT

All ABT fund holders →

FAQ

How long has Cardinal Strategic Wealth Guidance held ABT?

Cardinal Strategic Wealth Guidance has disclosed ABT holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

What is Cardinal Strategic Wealth Guidance's current position in ABT?

As of Q3 2026, Cardinal Strategic Wealth Guidance holds 2.77K shares of ABT (ABBOTT LABORATORIES), valued at $274.15K, representing 0.06% of its reported portfolio and ranking #48.

Has Cardinal Strategic Wealth Guidance been buying or selling ABT?

In the latest 13F filing (Q3 2026), Cardinal Strategic Wealth Guidance held unchanged its position in ABT. The position peaked in Q2 2025 at 2.78K shares.

Which other funds hold ABT?

Other major institutional holders of ABT include Vanguard Group, Charles Schwab Investment Management, CHARLES SCHWAB INVESTMENT MANAGEMENT INC, among 21 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.